PEDIATRIX MEDICAL GROUP INC

Company Overview

Pediatrix Medical Group is a national provider of physician services focused on newborn, maternal‑fetal and pediatric subspecialty care, delivering services through ~2,335 affiliated physicians across NICUs, PICUs and hospitalist programs in 36 states. The company generated roughly $2.01 billion of net revenue in 2024 and has shifted materially away from office‑based pediatrics toward hospital‑based neonatology and maternal‑fetal services, with ~67% of revenue concentrated in its five largest states (Texas ~32%). Its operating model bundles clinical care with centralized administration and data/telehealth platforms (BabySteps Cloud), and management has been executing a portfolio reshaping and revenue cycle management (RCM) transition that produced meaningful one‑time impairment and restructuring charges. Material exposures include heavy reliance on hospital contracting, Medicaid/government payors, A/R and collection performance, professional‑liability reserves and compliance with complex healthcare laws and audits.

Executive Compensation Practices

Compensation is likely tied to both financial recovery and quality/operational metrics: same‑unit revenue growth, adjusted EBITDA/adjusted EPS, operating cash flow and RCM collection/DPO/DSO improvements (DSO ~47.6 days; gross A/R ~$1.34B; collection sensitivity $6.4–$19.1M to net revenue) will be prime drivers of annual incentives. Given the sector and recent transformation, packages commonly combine base salary, annual cash bonuses keyed to short‑term operational targets and long‑term equity (RSUs/PSUs) that vest on multi‑year performance/TSR and strategic milestones (RCM implementation, hospital contract retention, margin restoration). Management has used one‑time/retention awards historically during disposals and restructurings; pay programs here are also likely to include compliance‑based clawbacks and explicit quality/safety KPIs (CQI, patient‑safety metrics) because regulatory and litigation risk (Anti‑Kickback, False Claims Act, HIPAA) can materially affect results. Debt and liquidity positions (term loans, $450M revolver unused at year‑end) and covenant considerations may constrain large discretionary payouts or share‑based transactions.

Insider Trading Considerations

Watch trading activity around material events that uniquely move Pediatrix’s fundamentals: quarterly earnings (when impairment recognition and RCM performance are disclosed), practice disposals, major hospital contract renewals/terminations, and regulatory/payor developments (No Surprises Act outcomes, Medicaid changes). Because earnings are sensitive to collections and A/R development, insider buying after positive DSO/A/R improvements or strong same‑unit reimbursement signals confidence in the operational turnaround; conversely opportunistic sales often cluster after impairment announcements or when executives rebalance concentrated stock positions. Expect formal blackout periods around earnings and material disclosures, and the prevalence of Rule 10b5‑1 plans or Section 16 reporting for officers and directors — any outsized insider activity should be cross‑checked against disclosed retention awards, restructuring payments or open trading plans that can explain timing.